
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp demonstrated a solid financial performance in the third quarter of 2025, reporting revenue of $21.5 million, which represents a 5% year-over-year increase attributed to the growing adoption of its Zephyr Endobronchial Valve. The company upheld a strong gross margin of 75% and improved its gross profit to $16.1 million, indicating efficient cost management amid a narrowed net loss of $14.0 million. Furthermore, Pulmonx's strategic initiatives in international markets, evidenced by a 15% sales increase to $7.5 million, along with ongoing investment in innovation and disciplined execution, underscore a positive long-term growth outlook.
Bears say
Pulmonx Corp experienced a sequential revenue decline in Q3, with reported revenue of approximately $21.5 million compared to $23.9 million in Q2, indicating a slowdown in financial performance that prompted a guidance revision for the year. The company's management transition, with Glen French returning as CEO and Derrick Sung appointed as COO/CFO, adds an element of uncertainty to operational execution, further heightening execution risks related to product models. Additionally, the pressure on top-line growth, along with a dip in gross margins from 72% in Q2 due to mix and conversion timing, reinforces concerns about the company's financial stability moving forward.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares